A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma

Table 2 Univariate and multivariate analysis of overall survival factors.

	N	Overall survival
		Univariable analysis		Multivariable analysis
		HR (95% CI)	P	HR (95% CI)	P
All	305
Age (years)			0.588
<60	106	Ref
≥60	199	0.929 (0.711-1.213)
Sex			0.916
Male	158	Ref
Female	147	1.007 (0.888-1.142)
T stage			< 0.001		< 0.001
T1-2	227	Ref		Ref
T3	78	1.744 (1.333-2.361)		2.065 (1.542-2.767)
N stage			< 0.001		< 0.001
N0-1	262	Ref		Ref
N2	43	2.487 (1.754-3.526)		3.049 (2.127-4.373)
AJCC stage			< 0.001		< 0.001
I-II	262	Ref		Ref
III	43	2.487 (1.754-3.526)		3.049 (2.127-4.373)
Grade			0.001		< 0.001
Well and moderate differentiation	191	Ref		Ref
Low differentiation	114	1.536 (1.187-1.989)		1.632 (1.255-2.124)
Intratumoral PD-L2			< 0.001		< 0.001
Low expression	238	Ref		Ref
High expression	67	1.858 (1.387-2.487)		1.892 (1.402-2.552)
Intratumoral CD3			0.07		0.003
Low cell densities	220	Ref		Ref
High cell densities	85	0.768 (0.577-1.022)		0.646 (0.482-0.865)
Stromal CD3			0.053		0.041
Low cell densities	119	Ref		Ref
High cell densities	186	1.295 (0.997-1.683)		1.319 (1.012-1.721)
Intratumoral CD8			0.143
Low cell densities	260	Ref
High cell densities	45	1.292 (0.917-1.821)
Stromal CD8			0.066		0.372
Low cell densities	272	Ref		Ref
High cell densities	33	0.663 (0.427-1.028)		0.814 (0.517-1.279)
Intratumoral FOXP3			0.006		0.002
Low cell densities	257	Ref		Ref
High cell densities	48	1.580 (1.138-2.193)		1.704 (1.215-2.389)
Stromal FOXP3			0.008		0.132
Low cell densities	292	Ref		Ref
High cell densities	13	2.157 (1.227-3.790)		1.647 (0.860-3.153)
Risk score			< 0.001		< 0.001
Low score	228	Ref		Ref
High score	77	2.047 (1.549-2.706)		1.836 (1.379-2.444)